ANNOUNCEMENT 22 Mar 2021

The Brazilian authorities approved 5 import tariff amendments leading both to an increase and a decrease in import tariffs on certain medicines and non-medical x-ray machinery.

 

NUMBER OF INTERVENTIONS

2

  • 1 harmful
  • 0 neutral
  • 1 liberalising

SOURCE

Official Gazette of Brazil. Diário Oficial da União. Órgão: Ministério da Economia/Câmara de Comércio Exterior/Comitê-Executivo de Gestão. Resoluçao Nº 175 de 22 de março de 2021. Available at: https://www.in.gov.br/en/web/dou/-/resolucao-gecex-n-175-de-22-de-marco-de-2021-309992038

Inception date: 01 Apr 2021 | Removal date: open ended

Import tariff

On 22 March 2021, the Executive Committee of the Brazilian Foreign Trade Chamber (Gecex) issued Resolution No. 175 eliminating the import tariffs on Risanquizumab, Ranibizumab, as well as Escherichia Coli bacterial lysate capsules. The affected products were classified under the tariff subheadings NCM 3002.15.90 and 3002.90.92.

According to the regulation, prior to this announcement, the affected goods enjoyed an import duty of 2% in the case of Risanquizumab and Ranibizumab, and of 4% in the case of Escherichia Coli bacterial lysate capsules.

Resolution No. 175 is to enter into force on 1 April 2021.

AFFECTED SECTORS

 

AFFECTED PRODUCTS

 
Inception date: 01 Apr 2021 | Removal date: open ended

Import tariff

On 22 March 2021, the Executive Committee of the Brazilian Foreign Trade Chamber (Gecex) issued Resolution No. 175 increasing the import tariffs on certain X-ray devices of the types used for luggage security inspection, as well as on X-ray devices of the types used for a vehicle safety inspection. the affected products were clñassified under the tariff subheading NCM 9022.19.99.

According to the regulation, prior to this announcement, the affected goods enjoyed an import duty of 0%.

Resolution No. 175 is to enter into force on 1 April 2021.